Over the last two decades, nanotechnology has become one of the most dynamically evolving field of research. Various types of nanoparticles are widely exploited to extend our understanding of biological interactions at the molecular level. They are actively engaged in the biomedical research for imaging, biosensing, drug delivery and/or concurrent therapy. Recent progress on this field is briefly reviewed here with an emphasis placed on the wide imaging applications of nanoparticles. Collectively, this field will no doubt make greater impact after we gradually address any potential risks of nanoparticles.
Feb 11
Read our review article on novel ‘Blue-sky’ future applications of nanoparticles in the Biomedical Field
Categories:
AD&T Notre Dame, Berthiaume Institute for Precision Health, Harper Cancer Research Institute, Review
by Prakash
Tags: NDNano
Recent Posts
- Phage-Mimicking Antibacterial Nanoparticles Tackle Group A Streptococcal Infections In Vivo January 29, 2024
- 2nd Annual Berthiaume Institute for Precision Health’s Advisory Board Meeting October 30, 2023
- 1st Place Poster at the Military Health Sciences Research Symposium 2023 (Aug 14-17, Kissimmee, FL) August 14, 2023
- Congratulations to Ms. Johanna Olesk on Defending her MS (Bioengineering) ’23 Thesis July 7, 2023
- Translational Science to Impact Public Health was our Goal at Techconnect 2023 June 17, 2023
Archives
Categories
NIH Funding Opportunities
- Request for Information (RFI): NIGMS Mature Synchrotron Program Evaluation May 17, 2024Notice NOT-GM-24-019 from the NIH Guide for Grants and Contracts
- Notice of Participation of the National Institute on Aging in RFA-HG-24-004, "ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites (UG3/UH3 Clinical Trials Not Allowed)" May 17, 2024Notice NOT-AG-24-019 from the NIH Guide for Grants and Contracts
- Notice of NIMHD Participation in RFA-OD-24-012, Predoctoral Training in Advanced Data Analytics for Behavioral and Social Sciences Research (BSSR) - Institutional Research Training Program [T32] May 17, 2024Notice NOT-MD-24-013 from the NIH Guide for Grants and Contracts
- Notice of Changes in NCI K00 Salary Caps in The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) May 17, 2024Notice NOT-CA-24-054 from the NIH Guide for Grants and Contracts
- Notice of Participation of NIDA in RFA-MH-25-186, "Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional)" May 16, 2024Notice NOT-DA-24-033 from the NIH Guide for Grants and Contracts
- OPEN House webinar for RFA-NS-24-030: NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00 Clinical Trial Not Allowed) May 16, 2024Notice NOT-NS-24-101 from the NIH Guide for Grants and Contracts
- Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed) May 16, 2024Funding Opportunity RFA-AG-25-024 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications proposing innovative strategies to target and manipulate brain cell subtypes that are altered in aging, Alzheimer's Disease (AD), and AD-Related Dementias (ADRDs). ADRDs include frontotemporal disorders (FTD), Lewy body dementia (LBD), vascular contributions to cognitive impairment […]
- NEI Research for Low Vision and Blindness Accessibility Tools (R61/R33 Clinical Trial Optional) May 16, 2024Funding Opportunity RFA-EY-24-003 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to stimulate translational efforts in developing and implementing accessibility devices or interventions that apply new technologies to address challenges faced by individuals living with visual impairment. Critical elements of applications include a clear set […]
- Notice of Intent to Publish a Funding Opportunity Announcement for RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed) May 15, 2024Notice NOT-CA-24-053 from the NIH Guide for Grants and Contracts
- Notice of Change to clarify the correct Component for Submission" used in RFA-DK-25-010 Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional) May 15, 2024Notice NOT-DK-24-021 from the NIH Guide for Grants and Contracts
Recent Comments